Suppr超能文献

丙硫氧嘧啶诱导的抗中性粒细胞胞浆抗体阳性的甲状腺功能亢进症患者的临床特征及结局

[Clinical features and outcomes of hyperthyroidism patients positive in propylthiouracil-induced antineutrophil cytoplasmic antibody].

作者信息

Ye Hua, Gao Ying, Guo Xiao-hui, Zhao Ming-hui

机构信息

Department of Endocrinology, Peking University First Hospital, Beijing 100034, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2005 Dec 14;85(47):3323-7.

Abstract

OBJECTIVE

To analyze the clinical features and outcomes of hyperthyroidism patients positive in propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA).

METHODS

The clinical data, including the clinical manifestations, treatment, and outcomes of 45 PTU-induced ANCA positive patients with hyperthyroidism were prospectively studied.

RESULTS

Seventeen of the 45 patients had clinically evident vasculitis and 28 of the 45 patients were not complicated by vasculitis. In the vasculitis group, 13 patients (76.5%) had renal involvement manifested by hematuria, proteinuria, and renal insufficiency. 7 of them (41.2%) had lung involvement and 6 of them had hemoptysis. Perinuclear ANCA (p-ANCA) was detected in all 17 patients and 16 of them (94.1%) were anti-myeloperoxidase antibodies (MPO-ANCA) positive. PTU was discontinued in all 17 patients and the treatment was switched over to methimazole (MMI) in 6 patients. Four patients with severe organ involvement received prednisone and immunosuppressant for 6 to 12 months. No relapse or death occurred during the follow-up period (8 to 60 months with a median of 30 months). All the 17 patients achieved clinical remission except for two that developed end stage renal disease due to late diagnosis. 27 of the 28 patients without vasculitis (96.4%) were p-ANCA positive and 14 of them (50.0%) were MPO-ANCA positive. PTU treatment was discontinued in 24 patients and switched over to MMI treatment in 15 patients, and 4 patients continued to take low dose PTU. No vasculitis manifestation occurred during the follow-up period (3 to 36 months with a median of 20 months). However, the ANCA titer declined slowly in most patients in both groups.

CONCLUSION

PTU treatment should be discontinued without delay in the PTU-induced ANCA positive patients with hyperthyroidism. Treatment can be switched over to MMI when necessary. Patients with severe organ involvement should receive prednisone and immunosuppressant. No vasculitis relapse is found during the follow-up after withdrawal of PTU. However, ANCA may keep positive for a long time.

摘要

目的

分析丙硫氧嘧啶(PTU)诱导的抗中性粒细胞胞浆抗体(ANCA)阳性的甲状腺功能亢进症患者的临床特征及转归。

方法

前瞻性研究45例PTU诱导的ANCA阳性的甲状腺功能亢进症患者的临床资料,包括临床表现、治疗及转归。

结果

45例患者中,17例有临床明显的血管炎,28例无血管炎并发症。血管炎组中,13例(76.5%)有肾脏受累,表现为血尿、蛋白尿和肾功能不全。其中7例(41.2%)有肺部受累,6例有咯血。17例患者均检测到核周型ANCA(p-ANCA),其中16例(94.1%)抗髓过氧化物酶抗体(MPO-ANCA)阳性。17例患者均停用PTU,6例换用甲巯咪唑(MMI)治疗。4例有严重器官受累的患者接受泼尼松和免疫抑制剂治疗6至12个月。随访期间(8至60个月,中位时间30个月)无复发或死亡。17例患者除2例因诊断延迟发展为终末期肾病外均达到临床缓解。28例无血管炎的患者中27例(96.4%)p-ANCA阳性,其中14例(50.0%)MPO-ANCA阳性。24例患者停用PTU治疗,15例换用MMI治疗,4例继续服用小剂量PTU。随访期间(3至36个月,中位时间20个月)无血管炎表现。然而,两组大多数患者的ANCA滴度下降缓慢。

结论

PTU诱导的ANCA阳性的甲状腺功能亢进症患者应立即停用PTU治疗。必要时可换用MMI治疗。有严重器官受累的患者应接受泼尼松和免疫抑制剂治疗。停用PTU后随访期间未发现血管炎复发。然而,ANCA可能会长期保持阳性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验